NVAX
Novavax Inc
NASDAQ: NVAX · HEALTHCARE · BIOTECHNOLOGY
$7.97
+0.63% today
Updated 2026-04-29
Market cap
$1.31B
P/E ratio
3.09
P/S ratio
1.17x
EPS (TTM)
$2.58
Dividend yield
—
52W range
$6 – $12
Volume
4.2M
Novavax Inc (NVAX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$7.97
12-Month target
$7.47
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.6B | $0.6B | $0.7B | $1.1B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 3.09x (capped 25x) · Margin: 39.20%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.